File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: GraphSynergy: A network-inspired deep learning model for anticancer drug combination prediction

TitleGraphSynergy: A network-inspired deep learning model for anticancer drug combination prediction
Authors
Keywordsanticancer
deep learning
drug combination
graph convolutional network
network
Issue Date2021
Citation
Journal of the American Medical Informatics Association, 2021, v. 28, n. 11, p. 2336-2345 How to Cite?
AbstractObjective: To develop an end-to-end deep learning framework based on a protein-protein interaction (PPI) network to make synergistic anticancer drug combination predictions. Materials and Methods: We propose a deep learning framework named Graph Convolutional Network for Drug Synergy (GraphSynergy). GraphSynergy adapts a spatial-based Graph Convolutional Network component to encode the high-order topological relationships in the PPI network of protein modules targeted by a pair of drugs, as well as the protein modules associated with a specific cancer cell line. The pharmacological effects of drug combinations are explicitly evaluated by their therapy and toxicity scores. An attention component is also introduced in GraphSynergy, which aims to capture the pivotal proteins that play a part in both PPI network and biomolecular interactions between drug combinations and cancer cell lines. Results: GraphSynergy outperforms the classic and state-of-the-art models in predicting synergistic drug combinations on the 2 latest drug combination datasets. Specifically, GraphSynergy achieves accuracy values of 0.7553 (11.94% improvement compared to DeepSynergy, the latest published drug combination prediction algorithm) and 0.7557 (10.95% improvement compared to DeepSynergy) on DrugCombDB and Oncology-Screen datasets, respectively. Furthermore, the proteins allocated with high contribution weights during the training of GraphSynergy are proved to play a role in view of molecular functions and biological processes, such as transcription and transcription regulation. Conclusion: The introduction of topological relations between drug combination and cell line within the PPI network can significantly improve the capability of synergistic drug combination identification.
Persistent Identifierhttp://hdl.handle.net/10722/330734
ISSN
2023 Impact Factor: 4.7
2023 SCImago Journal Rankings: 2.123
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYang, Jiannan-
dc.contributor.authorXu, Zhongzhi-
dc.contributor.authorWu, William Ka Kei-
dc.contributor.authorChu, Qian-
dc.contributor.authorZhang, Qingpeng-
dc.date.accessioned2023-09-05T12:13:43Z-
dc.date.available2023-09-05T12:13:43Z-
dc.date.issued2021-
dc.identifier.citationJournal of the American Medical Informatics Association, 2021, v. 28, n. 11, p. 2336-2345-
dc.identifier.issn1067-5027-
dc.identifier.urihttp://hdl.handle.net/10722/330734-
dc.description.abstractObjective: To develop an end-to-end deep learning framework based on a protein-protein interaction (PPI) network to make synergistic anticancer drug combination predictions. Materials and Methods: We propose a deep learning framework named Graph Convolutional Network for Drug Synergy (GraphSynergy). GraphSynergy adapts a spatial-based Graph Convolutional Network component to encode the high-order topological relationships in the PPI network of protein modules targeted by a pair of drugs, as well as the protein modules associated with a specific cancer cell line. The pharmacological effects of drug combinations are explicitly evaluated by their therapy and toxicity scores. An attention component is also introduced in GraphSynergy, which aims to capture the pivotal proteins that play a part in both PPI network and biomolecular interactions between drug combinations and cancer cell lines. Results: GraphSynergy outperforms the classic and state-of-the-art models in predicting synergistic drug combinations on the 2 latest drug combination datasets. Specifically, GraphSynergy achieves accuracy values of 0.7553 (11.94% improvement compared to DeepSynergy, the latest published drug combination prediction algorithm) and 0.7557 (10.95% improvement compared to DeepSynergy) on DrugCombDB and Oncology-Screen datasets, respectively. Furthermore, the proteins allocated with high contribution weights during the training of GraphSynergy are proved to play a role in view of molecular functions and biological processes, such as transcription and transcription regulation. Conclusion: The introduction of topological relations between drug combination and cell line within the PPI network can significantly improve the capability of synergistic drug combination identification.-
dc.languageeng-
dc.relation.ispartofJournal of the American Medical Informatics Association-
dc.subjectanticancer-
dc.subjectdeep learning-
dc.subjectdrug combination-
dc.subjectgraph convolutional network-
dc.subjectnetwork-
dc.titleGraphSynergy: A network-inspired deep learning model for anticancer drug combination prediction-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/jamia/ocab162-
dc.identifier.pmid34472609-
dc.identifier.scopuseid_2-s2.0-85118598623-
dc.identifier.volume28-
dc.identifier.issue11-
dc.identifier.spage2336-
dc.identifier.epage2345-
dc.identifier.eissn1527-974X-
dc.identifier.isiWOS:000711702400004-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats